XTLB · X.T.L. Biopharmaceuticals Ltd ADR
United States · RS rating 11 · As of 2026-11-03
| Price | 1.73 USD |
|---|---|
| 1-day change | +1.5% |
| RS rating (overall / 1M / 3M / 12M) | 11 / 20 / 14 / 17 |
| Stage | Declining |
| Composite / Minervini / CANSLIM score | 23 / 10 / 10 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | – |
| Sales growth Q/Q | +78.4% |
| Distance from 52-week high | +59.7% |
| Market cap (USD) | $5.8M |